Remnant cholesterol, C-reactive protein, cholesterol-lowering medication, and cardiovascular outcome: novel findings from UK Biobank
Findings support combined assessment of both biomarkers for personalized cardiovascular risk stratification and suggest effect modification by cholesterol-lowering medication reduces RC-related risk but not inflammation-driven risk in isolated CRP elevation.